Nitrosamines are organic compounds found in the human diet and other environmental outlets. Being potent carcinogens that can cause tumors in nearly all organs, they have been classified as genotoxic impurities (GTIs). There are guidelines and rulings by various regulatory organizations, including the FDA, EPA, EMA, and the IARC (International Agency for Research on Cancer). […]
Nitrosamines: An Overview Read More »
SK pharmteco will be attending the 14th Annual World ADC (Antibody-Drug Conjugate)Â Conference in London, 12th – 15th March 2024. This is Europe’s longest standing and definitive ADC event. SK pharmteco team members will be attending. You can schedule a meeting here and learn more about the World ADC here.
Meet us at the 2024 World ADC Conference Read More »
We will again be attending DCAT Week, March 18-21, 2024, the premier global event held each year in New York City for companies engaged in the Bio/Pharmaceutical manufacturing value chain. A wide range of SK pharmteco team members will be attending. You can schedule a meeting here and learn more about DCAT Week here.
Meet us at DCAT Week 2024 Read More »
The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors By Ji-Hyun Lee SK pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two new viral vector platforms that are expected to save the time and cost of
Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use Evry-Courcouronnes (near Paris), France, November 7, 2023 – Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), today launches AAVelocityTM,
RANCHO CORDOVA, Calif. and KING OF PRUSSIA, Pa., Oct. 18, 2023 /PRNewswire/ — SK pharmteco will participate at the CPHI 2023 in Barcelona and prepare a dedicated booth at the event. As a multi-modality CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pursue business opportunities. With a dedicated booth
SK pharmteco to Showcase its Extensive APIs and CGT Capabilities at CPHI 2023 Read More »
On Sept. 15, 2023, CPHI Barcelona announced the finalists for the 2023 CPHI Pharma Awards. The awards ceremony will be held on Oct. 24, 2023, the opening day of CPHI Barcelona, the world’s largest pharma event, at the Fiera Barcelona. SK pharmteco (SKPT) was honored to be among 12 finalists in the “Accelerating Innovation” category.
SK pharmteco is a Pharma Award Finalist for CPHI Barcelona 2023 Read More »
SK pharmeteco team members from many divisions will attend CPhI in Barcelona. The event takes place from 10/24/2023 to 10/26/2023 at the Fira Barcelona Gran Via. Learn more here. If you would like to set up a time to meet, please contact us here.
CPHI Barcelona: At the Heart of Pharma​ Read More »
RANCHO CORDOVA, CA – January 9, 2023 – SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, today announced that David Lowndes will be appointed as Chief Operating Officer. David will lead the company’s global Supply Chain, Quality, Regulatory Affairs, R&D, IT/Digital, and Operational Excellence functions through a period of significant
SK pharmteco Appoints David Lowndes as Chief Operating Officer Read More »
SK Inc. to invest $350M through SK pharmteco. SK Inc. announced on January 9th that it has invested $350 million in the Center for Breakthrough Medicines (CBM), a Pennsylvania-based CGT CDMO, to become the second-largest shareholder…
SK Inc. to invest $350M through SK pharmteco Read More »
"*" indicates required fields
